WeVote
Log In

Bill

Bill

S 2035

An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing

194th Legislature (2025-2026) Introduced by Jason Lewis and 1 co-sponsor

Massachusetts bill eliminates federal tax deductions for pharmaceutical companies' direct-to-consumer drug advertising, increasing their tax costs and potentially reducing marketing spending.

Reporting date extended to Thursday June 25, 2026
0
WeVote Research Nonpartisan
Bill Summary · S 2035

Legislative bill overview

S 2035 would eliminate the federal tax deduction that pharmaceutical companies can currently claim for direct-to-consumer (DTC) advertising expenses. This means drug manufacturers would no longer be able to deduct the costs of television, print, and digital ads targeting consumers directly from their taxable income, effectively increasing their tax liability for these marketing activities.

Why is this important

DTC pharmaceutical advertising is a multi-billion dollar industry in the United States, and this deduction significantly reduces its cost to manufacturers. Eliminating it could impact drug pricing strategies, potentially redirect marketing spending, and change the tax burden on pharmaceutical companies. The policy also raises questions about how Americans access information about medications and whether current advertising practices adequately serve public health interests.

Potential points of contention

  • Free speech arguments: Pharmaceutical companies may argue that restricting tax deductions for advertising infringes on commercial speech rights, even if advertising itself remains legal
  • Drug pricing complexity: Opponents question whether eliminating a tax deduction will meaningfully lower drug prices or simply increase pharmaceutical company profits, since marketing costs are often passed to consumers through higher drug prices
  • Consumer information access: Supporters of DTC advertising argue it educates patients about treatment options and encourages doctor consultations, while critics contend it drives unnecessary prescriptions and benefits only profitable medications
  • Competitiveness concerns: Industry advocates may argue the deduction elimination puts U.S. companies at a disadvantage compared to international competitors who can deduct similar expenses

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.